| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S7437 R21932 |
Bérard, 2017 | Genital organs malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.86 [0.37;1.99] | -/584 -/14,847 | - | 584 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5884 R14728 |
Ban (Controls unexposed, disease free), 2014 | Genital system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) |
0.91 [0.43;1.93] excluded (control group) |
-/1,946 1,292/325,294 | - | 1,946 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5885 R14743 |
Ban (Controls unexposed, sick), 2014 | Genital system malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.71 [0.32;1.56] | -/1,946 67/13,432 | - | 1,946 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10215 R37419 |
De Jonge, 2013 | Genital malformations | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No Monotherapy: no or not specified | 1.31 [0.08;21.42] C | 0/35 314/29,502 | 314 | 35 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6014 R15489 |
Jimenez-Solem (Controls unexposed, NOS), 2012 | Congenital malformations of the external genital organs | 1st trimester | population based cohort retrospective | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) |
1.70 [0.85;3.41] excluded (control group) |
8/1,606 2,504/843,797 | 2,512 | 1,606 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S6019 R15599 |
Jimenez-Solem (Controls unexposed, sick), 2012 | Congenital malformations of the external genital organs | 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 2.01 [0.43;9.50] C | 8/1,606 2/806 | 10 | 1,606 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 4 studies | 0.88 [0.52;1.50] | 324 | 4,171 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 6014, 5884